Suppliers / Jiangsu Chia Tai Fenghai Pharmaceutical

Jiangsu Chia Tai Fenghai Pharmaceutical

China 4 employees Updated 9 July 2026

Jiangsu Chia Tai Fenghai Pharmaceutical is an API manufacturer based in China. It holds 2 active US drug master files across a filed portfolio of 2 molecules.

2
active US DMFs
0
valid CEPs
0
registered plants
1
filings across 1 regulators

What they file, and where

Molecule Regulators Docs
Dexmedetomidine US FDA 1
Linezolid US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
UZPHARM (UZ) 1 None

Questions about Jiangsu Chia Tai Fenghai Pharmaceutical

Does Jiangsu Chia Tai Fenghai Pharmaceutical hold a US DMF or a CEP?
Jiangsu Chia Tai Fenghai Pharmaceutical holds 2 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
What does Jiangsu Chia Tai Fenghai Pharmaceutical make?
2 molecules are on record against Jiangsu Chia Tai Fenghai Pharmaceutical, including Dexmedetomidine and Linezolid. Each links through to that molecule's full manufacturer list.
Where does Jiangsu Chia Tai Fenghai Pharmaceutical file?
Filings are on record with UZPHARM (UZ), 1 in total.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Jiangsu Chia Tai Fenghai Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Comparable suppliers

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability